

# Maya Koren-Michowitz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5852541/publications.pdf>

Version: 2024-02-01

81  
papers

3,257  
citations

318942

23  
h-index

169272

56  
g-index

83  
all docs

83  
docs citations

83  
times ranked

6308  
citing authors

| #  | ARTICLE                                                                                                                                                                                                                                                       | IF  | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1  | Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapy. <i>Palliative Medicine</i> , 2021, 35, 927-932.                                                                                       | 1.3 | 8         |
| 2  | Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice. <i>American Journal of Hematology</i> , 2021, 96, 790-795.                                   | 2.0 | 20        |
| 3  | Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2314-2317.                                                                                            | 1.9 | 45        |
| 4  | <scp>BNT162b2 COVID</scp>â€19 vaccine is significantly less effective in patients with hematologic malignancies. <i>American Journal of Hematology</i> , 2021, 96, 1195-1203.                                                                                | 2.0 | 142       |
| 5  | COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. <i>Leukemia and Lymphoma</i> , 2021, 62, 3384-3393.                                                        | 0.6 | 25        |
| 6  | Hematological Biomarkers, Mortality, Transfusion and Acute Heart Disease. <i>American Journal of the Medical Sciences</i> , 2021, 362, 276-284.                                                                                                               | 0.4 | 1         |
| 7  | Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.                           | 0.6 | 1         |
| 8  | Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , 2020, 95, 156-166.                                                                       | 2.0 | 53        |
| 9  | Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets. <i>American Journal of Hematology</i> , 2020, 95, 379-386.                                                                        | 2.0 | 15        |
| 10 | Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group. <i>Acta Haematologica</i> , 2020, 144, 1-8.                                                                               | 0.7 | 0         |
| 11 | Venetoclax is safe and efficacious in relapsed/refractory AML. <i>Leukemia and Lymphoma</i> , 2020, 61, 2221-2225.                                                                                                                                            | 0.6 | 30        |
| 12 | Thrombocytopenia and thrombocytosis are associated with different outcome in atrial fibrillation patients on anticoagulant therapy. <i>PLoS ONE</i> , 2019, 14, e0224709.                                                                                     | 1.1 | 4         |
| 13 | Prevalence of Paroxysmal Nocturnal Hemoglobinuria Clones in Myeloproliferative Neoplasm Patients: A Cross-Sectional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 812-814.                                                                | 0.2 | 6         |
| 14 | Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remissionâ€a multi-center historical control study. <i>Annals of Hematology</i> , 2019, 98, 2711-2717. | 0.8 | 13        |
| 15 | A novel method for detecting the cellular stemness state in normal and leukemic human hematopoietic cells can predict disease outcome and drug sensitivity. <i>Leukemia</i> , 2019, 33, 2061-2077.                                                            | 3.3 | 13        |
| 16 | BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study. <i>Blood Advances</i> , 2019, 3, 3740-3749.                                                                                            | 2.5 | 10        |
| 17 | Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML. <i>Blood</i> , 2019, 134, 5091-5091.                                                                                                                                                          | 0.6 | 1         |
| 18 | Lower hemoglobin transfusion trigger is associated with higher mortality in patients hospitalized with pneumonia. <i>Medicine (United States)</i> , 2018, 97, e0192.                                                                                          | 0.4 | 7         |

| #  | ARTICLE                                                                                                                                                                                                                                                       | IF   | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 19 | Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. <i>Nature Medicine</i> , 2018, 24, 1867-1876.                                                                                                                    | 15.2 | 179       |
| 20 | Genetic Predisposition to Myeloproliferative Neoplasms: Another Piece of the Puzzle. <i>Acta Haematologica</i> , 2018, 139, 238-239.                                                                                                                          | 0.7  | 0         |
| 21 | Hemoglobin transfusion trigger in an internal medicine department – A "real world" six year experience. <i>PLoS ONE</i> , 2018, 13, e0193873.                                                                                                                 | 1.1  | 6         |
| 22 | Single cell analysis of multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8026-8026.                                                                                                                                                         | 0.8  | 1         |
| 23 | Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. <i>Leukemia Research</i> , 2017, 61, 6-9.                                                                                                                      | 0.4  | 5         |
| 24 | The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway. <i>Clinical Cancer Research</i> , 2017, 23, 1733-1747.                                                                                                    | 3.2  | 28        |
| 25 | Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey. <i>Annals of Hematology</i> , 2017, 96, 87-92.                                                                                                       | 0.8  | 13        |
| 26 | BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study. <i>Blood</i> , 2017, 130, 893-893.                                     | 0.6  | 1         |
| 27 | Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study. <i>Blood</i> , 2016, 128, 1650-1650. | 0.6  | 0         |
| 28 | Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 375-378.                                                                                              | 0.8  | 10        |
| 29 | Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Transplant Chronic Myeloid Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1852-1855.                            | 2.0  | 3         |
| 30 | Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice. <i>Leukemia Research</i> , 2015, 39, 1154-1158.                                                                                                                       | 0.4  | 13        |
| 31 | Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer</i> , 2015, 121, 863-871.                  | 2.0  | 48        |
| 32 | Anticoagulation Therapy for Venous Thrombotic Events in Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2015, 126, 4081-4081.                                                                                                                      | 0.6  | 0         |
| 33 | OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients. <i>European Journal of Haematology</i> , 2014, 92, 283-288.                                                                               | 1.1  | 31        |
| 34 | Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1155-1169.                                                              | 1.9  | 59        |
| 35 | Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects. <i>Blood</i> , 2014, 124, 3163-3163.                                                                                          | 0.6  | 1         |
| 36 | HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF). <i>Blood</i> , 2014, 124, 710-710.                                                    | 0.6  | 27        |

| #  | ARTICLE                                                                                                                                                                                                                                                                                                                  | IF  | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. <i>Oncotarget</i> , 2014, 5, 11283-11296.                                                                                                                              | 0.8 | 130       |
| 38 | S1P Modulator FTY720 Targets Multiple Myeloma Cell Proliferation and Stromal Interactions Via CXCR4/CXCL12 and mTOR Pathways. <i>Blood</i> , 2014, 124, 4707-4707.                                                                                                                                                       | 0.6 | 0         |
| 39 | Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting. <i>Blood</i> , 2014, 124, 1830-1830.                                                                                                                                                                                         | 0.6 | 0         |
| 40 | <i>&lt;i&gt;&lt;sc&gt;SH&lt;/sc&gt;2B3 (&lt;sc&gt;LNK&lt;/sc&gt;&lt;/i&gt; mutations from myeloproliferative neoplasms patients have mild loss of function against wild type <i>&lt;sc&gt;JAK&lt;/sc&gt;2</i> and <i>&lt;sc&gt;JAK&lt;/sc&gt;2 V617F</i>. <i>British Journal of Haematology</i>, 2013, 161, 811-820.</i> | 1.2 | 16        |
| 41 | JAK2V617F allele burden is associated with transformation to myelofibrosis. <i>Leukemia and Lymphoma</i> , 2012, 53, 2210-2213.                                                                                                                                                                                          | 0.6 | 22        |
| 42 | Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3. <i>Blood</i> , 2012, 120, 3310-3317.                                                                                                                                                                                                                 | 0.6 | 38        |
| 43 | Treatment with Interferon alpha prior to discontinuation of Imatinib in patients with chronic myeloid leukemia. <i>Cytokine</i> , 2012, 57, 290-293.                                                                                                                                                                     | 1.4 | 16        |
| 44 | Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. <i>Hematological Oncology</i> , 2012, 30, 200-205.                                                                                                                                                       | 0.8 | 33        |
| 45 | Older patients with normal karyotype acute myeloid leukemia have a higher rate of genomic changes compared to young patients as determined by SNP array analysis. <i>Leukemia Research</i> , 2012, 36, 467-473.                                                                                                          | 0.4 | 9         |
| 46 | Salvage Therapy with the Combination of ARA-C and Gemtuzumab Ozogamicin in Post-Allo-SCT High Risk AML Patients Is Feasible and Results in Modest Responses.. <i>Blood</i> , 2012, 120, 2629-2629.                                                                                                                       | 0.6 | 0         |
| 47 | A Sensitive Replicate RQ-PCR of BCR ABL Transcripts Suggests That A Large Portion of Long Term Post Allogeneic SCT CML Patients Are in Deep MR and May Therefore Be Cured From Their Disease. <i>Blood</i> , 2012, 120, 1690-1690.                                                                                       | 0.6 | 0         |
| 48 | Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML in Vitro and in Vivo. <i>Blood</i> , 2012, 120, 3735-3735.                                                                                                                                                | 0.6 | 0         |
| 49 | Update on JAK2 inhibitors in myeloproliferative neoplasm. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 61-71.                                                                                                                                                                                                    | 1.1 | 3         |
| 50 | Myeloid sarcoma: current approach and therapeutic options. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 309-316.                                                                                                                                                                                                 | 1.1 | 191       |
| 51 | Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosomeâ€“negative myeloproliferative neoplasms. <i>Blood</i> , 2010, 115, 2882-2890.                                                                                                                  | 0.6 | 116       |
| 52 | Correlation between losses of <i>&lt;i&gt;IGH&lt;/i&gt;</i> or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 17-27.                                                                                                                        | 1.5 | 17        |
| 53 | Activity and tolerability of nilotinib. <i>Cancer</i> , 2010, 116, 4564-4572.                                                                                                                                                                                                                                            | 2.0 | 20        |
| 54 | Adaptor protein Lnk inhibits c-Fms-mediated macrophage function. <i>Journal of Leukocyte Biology</i> , 2010, 88, 699-706.                                                                                                                                                                                                | 1.5 | 27        |

| #  | ARTICLE                                                                                                                                                                                                                                                                                                                           | IF  | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Adaptor Protein LNK Binds to and Is Phosphorylated by JAK3 and May Serve as a Scaffold for JAK3 Autophosphorylation In the Absence of An Appropriate Cytokine Receptor. <i>Blood</i> , 2010, 116, 2785-2785.                                                                                                                      | 0.6 | 3         |
| 56 | Older Patients with Normal Cytogenetics AML Have a Higher Rate of Genomic Changes Compared to Young Patients as Determined by SNP Chip Analysis. <i>Blood</i> , 2010, 116, 2479-2479.                                                                                                                                             | 0.6 | 0         |
| 57 | Adaptor Protein Lnk Negatively Regulates Bcr-Abl-Induced Cell Proliferation through Inhibition of the Stat5 Signaling Pathway.. <i>Blood</i> , 2010, 116, 3406-3406.                                                                                                                                                              | 0.6 | 0         |
| 58 | Attempt to Discontinue Imatinib Following Interferon Alfa Pre-Treatment In Chronic Phase CML Patients Achieving Stable Complete Cytogenetic Responses (CCyR). <i>Blood</i> , 2010, 116, 4898-4898.                                                                                                                                | 0.6 | 0         |
| 59 | Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia. <i>Leukemia</i> , 2009, 23, 190-194. | 3.3 | 44        |
| 60 | Oral integrity and salivary profile in myeloma patients undergoing high-dose therapy followed by autologous SCT. <i>Bone Marrow Transplantation</i> , 2009, 43, 801-806.                                                                                                                                                          | 1.3 | 21        |
| 61 | Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient. <i>PLoS Medicine</i> , 2009, 6, e1000029.                                                                                                                                                                               | 3.9 | 780       |
| 62 | Prior Response to Imatinib Predicts Response to Second Line Treatment with Nilotinib in CML Patients Resistant or Intolerant to Imatinib.. <i>Blood</i> , 2009, 114, 3297-3297.                                                                                                                                                   | 0.6 | 0         |
| 63 | Prevalence and Prognostic Impact of Allelic Imbalances Associated with Leukemic Transformation of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.. <i>Blood</i> , 2009, 114, 1280-1280.                                                                                                                            | 0.6 | 0         |
| 64 | A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). <i>Leukemia Research</i> , 2008, 32, 421-427.                                                                                         | 0.4 | 30        |
| 65 | Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. <i>Leukemia</i> , 2008, 22, 1961-1963.                                                               | 3.3 | 18        |
| 66 | The presence of a single PML-RARA isoform lacking exon 5 in FISH-negative APL samples. <i>Leukemia</i> , 2008, 22, 200-203.                                                                                                                                                                                                       | 3.3 | 5         |
| 67 | Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 3044-3051.                                                                                                                        | 3.2 | 634       |
| 68 | Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: A combined morphology and I-FISH analysis. <i>Cancer Letters</i> , 2007, 255, 307-314.                                                                                                    | 3.2 | 14        |
| 69 | High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations. <i>Leukemia</i> , 2007, 21, 1318-1321.                                                                                                                                                                                    | 3.3 | 39        |
| 70 | Symptoms of Posttraumatic Stress Disorder in Patients Who Have Had a Myocardial Infarction. <i>Psychosomatics</i> , 2006, 47, 231-239.                                                                                                                                                                                            | 2.5 | 63        |
| 71 | Tumor Lysis Syndrome Induced by Dexamethasone. <i>Anesthesiology</i> , 2006, 105, 633-634.                                                                                                                                                                                                                                        | 1.3 | 39        |
| 72 | Rituximab monotherapy as interim therapy in precursor B-ALL adults during periods of hepatic toxicity: Report of two cases. <i>American Journal of Hematology</i> , 2006, 81, 979-980.                                                                                                                                            | 2.0 | 10        |

| #  | ARTICLE                                                                                                                                                                                                                                                                                                                      | IF  | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 73 | Towards Stopping Imatinib Therapy under the Umbrella of Interferone: Alpha-Interferone Improves Molecular Response in CML Patients with Imatinib Induced Complete Cytogenetic Remission: An Early Observation from a Study of Pegylated Interferone in the Set up of Minimal Residual Disease.. Blood, 2006, 108, 4788-4788. | 0.6 | 0         |
| 74 | Near-Tetraploidy Can Mask the Presence of Chromosome 13q Deletions in Plasma Cells of Patients with Multiple Myeloma.. Blood, 2006, 108, 4280-4280.                                                                                                                                                                          | 0.6 | 0         |
| 75 | Protein Z and its role in venous and arterial thrombosis. Israel Medical Association Journal, 2006, 8, 53-5.                                                                                                                                                                                                                 | 0.1 | 7         |
| 76 | Protein Z levels and central retinal vein or artery occlusion. European Journal of Haematology, 2005, 75, 401-405.                                                                                                                                                                                                           | 1.1 | 17        |
| 77 | The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: A prospective open-label study. American Journal of Hypertension, 2005, 18, 358-363.                                                                                     | 1.0 | 40        |
| 78 | Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study. Pharmacoepidemiology and Drug Safety, 2004, 13, 299-302.                                                                                                                                                             | 0.9 | 24        |
| 79 | Enhanced Capacity of Monocytes from Patients with Essential Thrombocytemia to Generate Tissue Factor. Possible Mechanism of Thrombosis.. Blood, 2004, 104, 1937-1937.                                                                                                                                                        | 0.6 | 0         |
| 80 | Association of Protein Z Deficiency with Retinal Artery and Vein Occlusion.. Blood, 2004, 104, 3510-3510.                                                                                                                                                                                                                    | 0.6 | 0         |
| 81 | Monitoring Response to Osteoporosis Therapy With Alendronate by a Multisite Ultrasound Device. Journal of Clinical Densitometry, 2003, 6, 219-224.                                                                                                                                                                           | 0.5 | 10        |